Doreen Werchau

The CTLA-4 x OX40 bispecific antibody ATOR-1015 induces anti-tumor effects through tumor-directed immune activation

Anne Månsson Kvarnhammar, Niina Veitonmäki, Karin Hägerbrand et al. · Journal for ImmunoTherapy of Cancer · 2019 · 114 citations · Full text

Medicine, Immunology, Oncology +17

Bispecific antibodies targeting CD40 and tumor-associated antigens promote cross-priming of T cells resulting in an antitumor response superior to monospecific antibodies

Karin Hägerbrand, Laura A. Varas, Adnan Deronic et al. · Journal for ImmunoTherapy of Cancer · 2022 · 26 citations · Full text

Life Sciences, Immunology, Oncology +17

The human anti-CD40 agonist antibody mitazalimab (ADC-1013; JNJ-64457107) activates antigen-presenting cells, improves expansion of antigen-specific T cells, and enhances anti-tumor efficacy of a model cancer vaccine in vivo

Adnan Deronic, Anneli Nilsson, Mia Thagesson et al. · Cancer Immunology Immunotherapy · 2021 · 20 citations · Full text

Medicine, Cancer Biology, Immunology +17

The Bispecific Tumor Antigen-Conditional 4–1BB x 5T4 Agonist, ALG.APV-527, Mediates Strong T-Cell Activation and Potent Antitumor Activity in Preclinical Studies

Michelle H. Nelson, Sara Fritzell, Robert E. Miller et al. · Molecular Cancer Therapeutics · 2022 · 11 citations · Full text

Medicine, Immunology, Oncology +17